Solara Active Pharma Sciences Share Price Today | Stock Price & Solara Active Pharma Sciences Share Screener
As of November 19, 2026, the live Solara Active Pharma Sciences share price (NSE: SOLARA) is ₹640.60 on NSE and ₹639.30 on BSE, down 1.52% from the previous close, with shares trading between ₹638.50 and ₹651.30 in today's trading session, and a 52-week range of ₹425.55–₹753.25. Track Solara Active Pharma Sciences market cap to gauge the company's total market size. Use the Solara Active Pharma Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Solara Active Pharma Sciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹418 and net income of ₹29, with EBITDA of ₹73, an operating margin of 17.0% and a profit margin of 6.9%.
Solara Active Pharma Sciences Share Price Chart
Track the current stock price of Solara Active Pharma Sciences with an interactive chart. Analyse SOLARA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Solara Active Pharma Sciences stock quote in one place.
The quote of ₹640.60 sits between the 52-week low of ₹425.55 and the 52-week high of ₹753.25, and the latest session moved -1.52% from the previous close.
Solara Active Pharma Sciences Company Profile - Fundamental Screener
Screen Solara Active Pharma Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SOLARA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE624Z01016.
Company Details
Classification
Identifiers and Leadership
Solara Active Pharma Sciences Balance Sheet Screener
Screen SOLARA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹2,333, up from ₹2,232 in 2025.
Latest statistics put total assets at ₹2,333 and shareholder funds at ₹1,256, with a leverage ratio of 0.63.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
Assets |
|||||||||
| Total Assets | 2,333 | 2,232 | 2,351 | 2,899 | 2,945 | 2,614 | 2,154 | 1,960 | 1,822 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 1,238 | 1,193 | 1,268 | 1,364 | 1,356 | 1,382 | 1,397 | 1,218 | 1,086 |
Liabilities |
|||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 183 | 191 | 172 | 296 | 354 | 232 | 333 | 344 | 315 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||||
| Total Equity | 1,256 | 1,097 | 937 | 1,502 | 1,527 | 1,593 | 1,090 | 960 | 769 |
| Share Capital | 45 | 40 | 36 | 36 | 36 | 36 | 27 | 26 | 25 |
| Reserves & Surplus | 1,208 | 1,054 | 898 | 1,464 | 1,489 | 1,553 | 963 | 826 | 739 |
Solara Active Pharma Sciences Income Statement Screener - Profit & Revenue Analysis
Screen Solara Active Pharma Sciences income statement and profit fundamentals. Analyze SOLARA quarterly results. Solara Active Pharma Sciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹418 and net profit was ₹29, equal to earnings per unit of ₹5.92, at an operating margin of 17%.
In that period expenses were ₹345, interest cost ₹18 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹384 and net profit of ₹16.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 418 | 384 | 393 | 349 | 314 | 320 | 279 | 302 | 347 | 364 | 301 | 212 | 426 | 354 | 385 |
| Expenses | 345 | 320 | 330 | 318 | 279 | 262 | 228 | 243 | 286 | 322 | 412 | 436 | 393 | 333 | 332 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 73 | 65 | 63 | 31 | 35 | 58 | 51 | 59 | 62 | 43 | -111 | -224 | 34 | 21 | 53 |
| Operating Profit % | 17.00% | 16.00% | 15.00% | 9.00% | 11.00% | 18.00% | 17.00% | 19.00% | 18.00% | 12.00% | -38.00% | -106.00% | 8.00% | 5.00% | 13.00% |
| Depreciation | 27 | 27 | 26 | 26 | 25 | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 26 | 26 | 27 |
| Interest | 18 | 22 | 28 | 23 | 21 | 24 | 29 | 27 | 28 | 31 | 31 | 25 | 24 | 25 | 22 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 29 | 16 | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -14 | -167 | -275 | -17 | -29 | 5 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89 | 0 | 0 | -10 | 1 |
| Net Profit | 29 | 16 | 10 | -17 | -10 | 11 | -2 | 8 | 8 | -14 | -255 | -275 | -17 | -19 | 4 |
| EPS | 5.92 | 3.52 | 2.20 | -3.98 | -2.36 | 2.46 | -0.93 | 2.03 | 2.54 | -3.50 | -70.93 | -72.07 | -4.77 | -5.43 | 1.05 |
Solara Active Pharma Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SOLARA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹153, and net cash flow was an inflow of ₹1.
Over the same period, investing activities used ₹99 and financing activities used ₹54.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||||
| Operating Activities | 153 | 213 | 109 | 156 | -242 | 156 | 242 | 166 | 49 |
| Investing Activities | -99 | -37 | -4 | -81 | -243 | -106 | -359 | -113 | -86 |
Financing and Net Cash | |||||||||
| Financing Activities | -54 | -181 | -106 | -113 | 334 | 93 | 97 | -23 | 68 |
| Net Cash Flow | 1 | -5 | 0 | -38 | -151 | 142 | -20 | 30 | 32 |
Solara Active Pharma Sciences Shareholding Pattern Screener
See Solara Active Pharma Sciences shareholding pattern with promoter, FII, and DII holdings. Check Solara Active Pharma Sciences promoter holding and ownership changes for SOLARA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 41.93%, foreign institutions 10.71%, domestic institutions 3.89% and the public 27.62%, spread across 70,905 shareholders.
The shareholder count was 70,905 in 2026-Sept, compared with 70,490 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2026-May | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 41.93% | 41.93% | 42.00% | 42.00% | 42.00% | 42.01% | 42.01% | 37.94% |
Institutional Investors | ||||||||
| FII Holding | 10.71% | 11.52% | 11.59% | 11.33% | 11.98% | 13.58% | 14.25% | 14.63% |
| DII Holding | 3.89% | 3.74% | 3.75% | 3.78% | 3.64% | 2.69% | 2.62% | 2.61% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 27.62% | 25.84% | 25.03% | 25.15% | 24.63% | 24.01% | 23.47% | 23.07% |
| Other Holding | 15.84% | 16.97% | 17.63% | 17.74% | 17.74% | 17.70% | 17.63% | 21.74% |
| Shareholder Count | 70,905 | 70,490 | 70,400 | 70,037 | 71,920 | 72,479 | 74,334 | 75,791 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Solara Active Pharma Sciences. Solara Active Pharma Sciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹3.00 | 0.88% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹7.00 | 1.14% |
| 2020-March | ₹2.00 | 0.16% |
| 2019-March | ₹5.00 | 1.22% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Solara Active Pharma Sciences Stock Index Membership - Nifty & Sensex
See which indices include Solara Active Pharma Sciences stock. Check SOLARA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Solara Active Pharma Sciences Market Events Screener - Corporate Actions
Get Solara Active Pharma Sciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Solara Active Pharma Sciences stock events that may affect SOLARA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 16, 2026, with a record date of October 16, 2026.
It is followed by Annual General Meeting dated September 18, 2026 and Quarterly Result Announcement dated July 23, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-16 | 2026-10-16 | Quarterly Result Announcement | NA | -0.32% |
| 2026-09-18 | 2026-09-18 | Annual General Meeting | NA | 18.04% |
| 2026-07-23 | 2026-07-23 | Quarterly Result Announcement | NA | -7.13% |
| 2026-05-15 | 2026-05-15 | Quarterly Result Announcement | NA | -1.55% |
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 3.68% |
| 2025-11-05 | 2025-11-05 | Quarterly Result Announcement | NA | 4.97% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | 1.99% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | -5.15% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 19.48% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.29% |
| 2024-10-21 | 2024-10-21 | Quarterly Result Announcement | NA | 8.18% |
| 2024-09-20 | 2024-09-20 | Annual General Meeting | NA | 6.04% |
| 2024-05-15 | 2024-05-15 | Rights | 1:3 | 8.26% |
| 2021-08-18 | 2021-08-20 | Dividend | ₹ 3.00 /share | 5.36% |
| 2017-03-25 | 2017-03-25 | Change Of Name | NA | - |
Solara Active Pharma Sciences Competitors Screener - Peer Stocks Comparison
Screen SOLARA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,676 | 40.80 | 61,674 | 12.69% | 11,565 | 60.46 |
| Divis Laboratories | 295,997 | 87.70 | 11,067 | 13.95% | 2,568 | 68.76 |
| Torrent Pharmaceuticals | 177,586 | 85.00 | 13,886 | 20.34% | 2,138 | 47.23 |
| Laurus Labs | 126,325 | 89.90 | 6,868 | 22.01% | 890 | 57.04 |
| Zydus Life Science | 120,119 | 27.60 | 27,658 | 17.64% | 5,026 | 55.91 |
| Dr Reddys Laboratories | 115,854 | 41.80 | 35,059 | 3.90% | 4,158 | 71.26 |
| Cipla | 112,131 | 39.50 | 29,045 | 2.24% | 3,870 | 53.06 |
| Mankind Pharma | 107,805 | 47.90 | 14,636 | 14.85% | 1,938 | 61.37 |
| Aurobindo Pharma | 103,229 | 25.80 | 34,145 | 5.56% | 3,503 | 60.39 |
| Lupin | 89,172 | 17.30 | 29,039 | 26.75% | 5,356 | 39.39 |
Solara Active Pharma Sciences Company Announcements - News & Reports Screener
Screen SOLARA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 23, 2026.
The next most recent announcements are dated October 19, 2026 and October 17, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-23 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-10-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-17 | Final Reminder-Cum-Forfeiture Notice To The Holders Of Partly Paid-Up Equity Shares Of The Company. | - |
| 2026-10-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-10-16 | Statement Of Deviation / Variation In Utilization Of Funds Raised For The Quarter Ended September 30 2026. | - |
| 2026-10-16 | Grant Of Employee Stock Options Under Solara Employee Stock Option Plan 2024. | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-10-16 | Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-16 | Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026. | - |
| 2026-10-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-10 | Intimation Of ESG Rating | - |
| 2026-10-09 | Update On Rights Issue - Final Reminder Cum Forfeiture Notice | - |
| 2026-10-09 | Board Meeting Intimation for Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-26 | Intimation To Furnish Valid PAN KYC Details And Nomination By Shareholders Holding Physical Shares | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-09-22 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹640.60, within a 52-week range of ₹425.55 to ₹753.25. The P/E ratio is 83.40 and the P/B ratio is 2.14, with earnings per unit of ₹-1.68. Market capitalisation stands at ₹3,202.92 Cr and the dividend yield is 0.47%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 9 balance sheet periods, 15 income statement periods, 9 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.